Аутизм и нарушения развития 2012. Том. 10, № 4. С. 1–18
ISSN:
1994-1617 / 2413-4317 (online)
Лекарственная терапия расстройств аутистического спектра у детей: опыт зарубежных психофармакологов 4839
Бородина Л.Г. кандидат медицинских наук, детский психиатр, доцент кафедры клинической и судебной психологии факультета юридической психологии, ФГБОУ ВО МГППУ, Москва, Россия e-mail: bor111a@yandex.ru
За последние десятилетия число детей, страдающих расстройствами
аутистического спектра (РАС), возрастает в катастрофических масштабах. Если
около 30-ти лет назад частота встречаемости аутизма равнялась 1 на 10 000 (1),
то в настоящее время исследования поражают выявляемыми данными: 1 на 110 детей
в США [4], 1% общей популяции [32], 50 – 100 на 10 000 у наших авторов [3].
Роль улучшившейся диагностики аутизма не превышает 1/3 от общего увеличения его
случаев [16]. Споры о том, целесообразна ли психофармакотерапия у детей с РАС,
продолжаются. Если отечественная психиатрическая школа считает её необходимой и
оправданной в большинстве случаев [1, 2, 3], то за рубежом существуют различные
мнения на этот счёт. Тем не менее, от 35 до 50% детей с аутизмом в США и Канаде
получают как минимум один психотропный препарат, а 50–70% – различные БАДы и
«альтернативные» методы лечения [4]. У 74% детей используются новые, не
одобренные FDA, препараты и средства [63].
Литература
Башина В.М., Симашкова Н.В. Аутизм в детстве // В.М. Башина.
Лечение и реабилитация. – М.: – Медицина, 1999. – С. 171 206.
Козловская Г.В., Калинина М.А., Горюнова А.В., Проселкова М.Е.
Опыт применения рисполепта при лечении раннего детского аутизма и шизофрении у
детей // Психиатрия и психофармакотерапия. – Приложения. – Т. 1/N. –
2/2000.
Симашкова Н.В. Эффективная фармакотерапия и реабилитация больных с
расстройствами аутистического спектра // Неврология и психиатрия. – 2011. – №
3. – С. 14-22.
Anagnostou E., Hansen Rl. Medical treatment overview: traditional
and novel psychopharmacological and complementary and alternative medications
// Curr Opin Pediatr. 2011 Dec; 23(6): 621-7.
Andari E., Duhamel J.R., Zolla T., et al. Promoting social
behavior with oxytocin in high functioning autism spectrum disorder // Proc
Natl Acad Sci USA. 2010 Mar 2; 107(9): 4389-94.
Anderson L.T., Campbell M., Adams P., et al. The effects of
haloperidol on discrimination learning and behavioral symptoms in autistic
children // J Autism Dev Disord. 1989 Jan; 19(2): 227-39.
Baghdadli A., Gounier V., Aussilloux G. Review of
psychopharmacological treatments in adolescents and adults with autistic
disorders. // Encephale. 2002 May-June; 28(3Pt1): 248-54.
Banaschewski T., Poustka L., Holtmann M. Autism and ADHD across
the life span. Differential diagnoses or comordidity? // Nervenarzt. 2011 May;
82(5): 573-80.
Barnard L., Young A.H., Pearson J., et al. A systematic review of
the use of atypical antipsychotics in autism //J Psychopharmacol. 2002 Mar
16(1): 93-101.
Bradstreet J.J., Smith S., Granpeesheh D. et al. Spironolactone
might be a desirable immunologic and hormonal intervention in autism spectrum
disorders // Med Hypotheses. 2007; 68(5): 979-87.
Branford D., Bhaumik S., Naik B. Selective serotonin re-uptake
inyibitors for the treatment of perseverative and maladaptive behaviors of
people with intellectual disability // J Intellect Disabil Res. 1998 Aug;
42(Pt40:301-6.
Chabrol H., Bonnet D., Roge B. Psychopharmacology of autism //
Encephale. 1996 May-June; 22(3):197-203.
Chanizadeh A. Atomoxetine for Treating ADHD symptoms in Autism: a
Systematic Review // J Atten Disord. 2012 Apr 27 (Epub ahead of print).
Charnsil C. Efficacy of atomoxetine in children with severe
autistic disorders and symptoms of ADHD: an open-label study // J Atten Disord.
2011 Nov; 15(8): 684-9.
Chez M.G., Guido-Estrada N. Immune therapy in autism: historical
experience and future directions with immunomodulatory therapy //
Neurotheraputics. 2010 Jul; 7(3): 293-301.
Coo H., Quellette-Kuntz H., Lloyd J.E., et al. Trends in autism
prevalence: diagnostic substitution revisited // J Autism Dev Disord. 2008 Jul;
38(6): 1036-46.
DeLong GR, Ritch CR, Busch S. Fluoxetine response in children with
autistic spectrum disorders: correlation with familial major affective disorder
and intellectual achievtment // Dev Med Child Neurol. 2002 Oct
44(10):652-9.
Dollfus S., Petit M., Menard J.F., et al. Amisulpride versus
bromocriptine in infantile autism: a controlled crossover comparative study of
two drugs with opposite effects on dopaminergic function // J Autism Dev
Disord. 1992 Mar; 22(1): 47-60.
Elbe D., Lalani Z. Review of the pharmacotherapy of irritability
of autism // J Can Acad Child Adolesc Psychiatry. 2012 May; 21(2): 130-46.
Fink H., Taylor M.A., Chaziuddin N. Catatonia in autistic spectrum
disorders: a medical treatment algorithm // Int Rev Neurobiol.2006; 72:
233-44.
Frye R.E., Huffman L.C., Elliott G.R. Tetrahydrobiopterin as a
novel therapeutic intrvtntion for autism // Neurotheraputics. 2010 Jul; 7(3):
241-9.
Frye R.E., Sreenivasula S., Adams J.B. Traditional and
non-traditional treatments for autism spectrum disorders with seizures: an
on-line survey. BMC Pediatr. 2011 May 18; 11-37.
Garcia-Penas J.J. Antiepileptic drugs in the treatment of autistic
regression syndrome // Rev Neurol. 2005 Jan 15; 40 Suppl 1: s 173-6.
Goiness P., Van de Water J. The immune system`s role in the
biology of autism // Curr Opin Neurol. 2010 Apr; 23(2): 111-7.
Gralton E.J., james D.H., Lindsey M.P. Antipsychotic medication,
psychiatric diagnosis and children with intellectual disability // J Intellect
Disabil Res. 1998 Feb; 42(Pt1): 49-57.
Green J.J., Hollander E. Autism and oxytocin: new developments in
translational approaches to therapeutics // Neurotheraputics. 2010 Jul; 7(3):
250-7.
Guastella A.J., Einfeld S.L., Gray R.M. et al. Intranasal oxytocin
improves emotion recognition for youth with autism spectrum disorder // Biol
Psychiatry. 2010 Apr 1; 6797): 692-4.
Hjiej H., Doyen C., Couprie C., Kaye K., et al. Substitutive and
dietic approaches in childhood autistic disorder: interests and limits //
Encephale. 2008 Oct; 34(5): 496-503.
Hollander E., Chaplin W., Soorya L., et al. Divalproex sodium vs
placebo for the treatment of irritability in children and adolescents with
autism spectrum disorders // Neuropsychopharmacology. 2010 Mar; 35(4):
990-8.
Huffman L.S., Sutcliffe T.L., Tanner I.S., et al. Management of
symptoms in children with autism spectrum disorders: a comprehensive review of
pharmacologic and complementary – alternative medicine treatments // J Dev
Behav Pediatr. 2011 Jan; 32 (1): 56-68.
James S., Montgomery P., Williams K. Omega-3 fatty acids
supplementation for autism spectrum disorders (ASD) // Cochrane Database Syst
Rev. 2011 Nov 9; (11): CD 007992.
Janusonis S. Origin of the blood hyperserotoninemia of autism //
Theor Biol Med Model. 2008 Mar; 3(1): 355-62.
Jorgensen O.S. Psychopharmacological treatment of psychotic
children. A survey // Acta Psychiatr Scand. 1979 Feb; 59 (2):229-38.
Kakooza-Mwesige A., Wachtel L.E., Dhosshe D.M. Catatonia in
autism: implications across the life span // Eur Child Adolesc Psychiatry. 2008
Sep; 17(6):327-35.
Kaplan G., McCracken J.T. Psychopharmacology of autism spectrum
disorders // Pediatr Clin North Am. 2012 Feb; 59:175-87.
King C.R. A novel embryological theory of autism causation
involving endogenous biochemicals capable of initiating cellular gene
transcription: a possible link between twelve autism risk factors and the
autism “epidemic”// Med Hypotheses. 2011 May; 76(5): 653-60.
Krishnaswami S., McPheeters M.L., Veenstra-Vanderweele J. A
systematic review of secretin for children with autism spectrum disorders //
Pediatrics. 2011 May; 127 (5): e 1322-5.
Leventhal B.L., Cook E.V. Jr, Morford M., et al. Clinical and
neurochemical effects of fenfluramine in children with autism // J
Neuropsychiatry Clin Neurosci. 1993 Summer; 5(3): 307-15.
Linday L.A. Oral famotidine: a potential treatment for children
with autism // Med Hypotheses. 1997 May; 48(5): 381-6.
Linday L.A., Tsiouris J.A., Cohen I.L., et al. Famotidine
treatment for children with autistic spectrum disorders: pilot research using
single subject research design // J Neurol Transm. 2001; 108(5): 593-611.
Luby J., Mrakotsky C., Stalets M.M., et al. Risperidone in
preschool children with autism spectrum disorders: an investigation of safety
and efficacy // J Child Adolesc Psychopharmacol. 2006 Oct; 16(5): 575-87.
Marrosu F., Marrozu G., Rachel M.G., et al. Paradoxical reactions
elicited by diazepam in children with classic autism // Funet Neurol. 1987
Jul-Sep; 2(3): 355-61.
Matarazzo E.B. Treatment of late onset autism as a a consequence
of probable autoimmune processes related to chronic bacterial infection //
World J Biol Psychiatry. 2002 Jul; 3(3): 162-6.
McCracken J.T. Safety issues with drug therapies for autism
spectrum disorder // J Clin Psychiatry. 2005; 66 Suppl. 10: 32-7.
McDougle C.L., Brodkin E.S., Naylor S.T., et al. Sertraline in
adults with pervasive developmental disorders: a prospective open-label
investigation // J Clin Psychopharmacol. 1998 Feb; 18(1): 62-6.
McDougle C.L., Kresch L.E., Posey D.G. Repetetive thoughts and
behavior in pervasive developmental disorders: treatment with serotonin
reuptake inhibitors // J Autism Dev Disord. 2000 Oct; 30(5): 427-35.
McDougle C.L., Kem D.L., Posey D.G. Case series: use of
ziprasidone for maladaptive symptoms in youth with autism // J Am Acad Child
Adolesc Psychiatry. 2002 Aug; 41(8): 921-7.
McKinney C., Renk K. Atypical antipsychotic medications in the
management of disruptive behaviors in children: safety guidelines and
recommendations // Clin Psychol Rev. 2011 Apr; 31(3): 465-71.
McPheeters M.L., Warren Z., Sathe N. A systematic review of
medical treatments for children with autism spectrum disorders // Pediatrics.
2011 vol. 127 №5 May 1: e 1312-1321.
Millward C., Ferriter M., Calver S., et al. Gluten– and casein–
free diet for autistic spectrum disorders // Cochrane Database Syst Rev. 2008
Apr 16(2): CD 003498.
Ming X., Julu P.O., Brimacombe M., et al. Reduced cardiac
parasympathetic activity in children with autism // Brain Dev. – 2005. – vol.
5. – 486-93.
Modi M.E., Young L.J. The oxytocin system in drug discovery for
autism: animal models and novel therapeutic strategies // Horm Behav. 2012 Mar;
61 (3): 340-50.
Moscal J.R., Burqdorf J. A novel NMDA receptor glycine-syte
partial agonist GLYX- 13 has therapeutic potential for the treatment of autism
// Neurosci Biobehav Rev. 2011 Oct; 35(9): 1982-8.
Newcomer J.W. Second-generation (atypical) antipsycotics and
metabolic effects: a comprehensive literature review // CNS Drugs. 2005; 19
suppl. 1: 1-93.
Niederhofer H., Staffen W., Mair A. Galantamine might be effective
in treating autistic disorder // BMJ. 2002 Dec 14; 325 (7377): 1422.
Posey D.J., Walsh K.H., Wilson G.A., et al. Risperidone in the
treatment of two very young children with autism // J Child Adolesc
Psychopharmacol. 1999; 9 (4): 273-6.
Posey D.J., McDougle C.J. The pharmacotherapy of target symptoms
associated with autistic disorder and other pervasive developmental disorders
// Harv Pev psychiatry. 2000 Jul-Aug; 8(2): 45-63.
Posey D.J., Puntney J.I., Sasher T.M., et al. Guanfacine treatment
of hyperactivity and inattention in pervasive developmental disorders: a
retrospective analysis of 80 cases // J Child Adolesc Psychopharmacol. 2004
Summer; 14(2): 233-41
Posey D.J., Erickson C.A., McDougle C.J. Developing drugs for core
social and communication impairment in autism // Child Adolesc Psychiatr Clin N
Am. 2008 Oct; 17(4): 787.
Poustka L., Banaschewski T., Poustka F. Psychopharmacology of
autism spectrum disorders // Nervenarzt. 2011 May; 82(5): 582-9.
Rajapakse T., Pringsheim T. Pharmacotheraputics of Tourette
syndrome and stereotypes in autism // Semin Pediatr Neurol. 2010 Dec; 17(4):
254-60.
Realmuto G.M., August G.J., Garfinkel B.D. Clinical effect of
buspirone in autistic children // J Clin Psychopharmacol. 1989 Apr; 9(2): 122
5.
Robb A.S. Managing irritability and aggression in autism spectrum
disorders in children and adolescents//Dev Disabil Res Rev 2010; 16(3):
258-64.
Rossignol D.A. Novel and emerging treatments for autism spectrum
disorder: a systematic review // Ann Clin Psychiatry. 2009 Oct-Dec; 21(4):
213-36.
Rossignol D.A., Frye R.E. Melatonin in autism spectrum disorders:
a systematic review and meta-analysis // Dev Med Child Neurol. 2011 Sep; 53(9):
783-92.
Possignol D.A., Frye R.E. Mitochondrial dysfunction in autism
spectrum disorders: a systematic review and meta-analysis // Mol Psychiatry.
2012 Mar; 17(3): 290-314.
Rothenberger A. Psychopharmacological treatment of self-injurious
behavior in individuals with autism // Acta Paedopsychiatr. 1993; 56(2):
99-103.
Rugino T.A., Samsock T.C. Levetiracetam in autistic children: an
open-label study // J Dev behave Pediatr. 2002 Aug; 23(4): 22-30.
Shattock P., Whiteley P. Biochemical aspects in autism spectrum
disorders: updating the opioid-excess theory and presenting new opportunities
for biomedical intervention // Expert Opin Theor Targets. 2002 Apr; 6(2):
175-183.
Sloman L. Use of medication in pervasive developmental disorders
// Psychiatr Clin North Am. 1991 Mar; 14(1): 165-82.
Stachnik J.M., Nunn-Thompson C. Use of atypical antipsychotics in
the treatment of autistic disorder // Ann Pharmacother. 2007 Apr; 41(4):
626-34.
Wei H., Dobkin C., Sheikh F.M., et al. the therapeutic effect of
memantine through the stimulanion of synapse formation and dendritic spine
maturation in autism and fragile X syndrome // PLoS One. 2012; 7(5): e
36981.
White S.W., Oswald D., Ollendick T., et al. Anxiety in children
and adolescents with autism spectrum disorders // Clin Psychol Rev. 2009 Apr;
29(3): 216-229.
Zuddas A., Di Martino A., Muglia P., et al. Long-term risperidone
for pervasive developmental disorder: efficacy, tolerability, and
discontinuation // J Child Adolesc Psychopharmacol. 2000 Summer; 10(2):
79-90.